0001628280-26-027597.txt : 20260427 0001628280-26-027597.hdr.sgml : 20260427 20260427170033 ACCESSION NUMBER: 0001628280-26-027597 CONFORMED SUBMISSION TYPE: 144 PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20260427 DATE AS OF CHANGE: 20260427 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Werewolf Therapeutics, Inc. CENTRAL INDEX KEY: 0001785530 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 823523180 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 144 SEC ACT: 1933 Act SEC FILE NUMBER: 001-40366 FILM NUMBER: 26901871 BUSINESS ADDRESS: STREET 1: 200 TALCOTT AVENUE STREET 2: 2ND FLOOR CITY: WATERTOWN STATE: MA ZIP: 02472 BUSINESS PHONE: 617-952-0555 MAIL ADDRESS: STREET 1: 200 TALCOTT AVENUE STREET 2: 2ND FLOOR CITY: WATERTOWN STATE: MA ZIP: 02472 REPORTING-OWNER: COMPANY DATA: COMPANY CONFORMED NAME: UBS Oncology Impact Fund L.P. CENTRAL INDEX KEY: 0001691428 ORGANIZATION NAME: EIN: 000000000 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 144 BUSINESS ADDRESS: STREET 1: 399 BOYLSTON STREET STREET 2: SUITE 1100 CITY: BOSTON STATE: MA ZIP: 02142 BUSINESS PHONE: 617-425-9200 MAIL ADDRESS: STREET 1: 399 BOYLSTON STREET STREET 2: SUITE 1100 CITY: BOSTON STATE: MA ZIP: 02142 144 1 primary_doc.xml 144 0001691428 XXXXXXXX LIVE 0001785530 Werewolf Therapeutics, Inc. 001-40366 200 Talcott Avenue 2nd Floor Watertown MA 02472 6179520555 UBS Oncology Impact Fund, L.P. Shareholder Common Merrill Lynch 555 California Street 18th Floor San Francisco CA 94104 107652 87521.08 48596817 04/27/2026 NASDAQ Common 05/04/2021 Private Placement Issuer N 107652 05/04/2021 Cash Y 04/27/2026 03/26/2026 Kristen Laguerre